Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

>Guidance

The Company currently expects that sales for 2010, excluding the impact of foreign currency, will be between a decline of 5% and an increase of 1% versus 2009.  Full year 2010 EBITDA is currently expected to be between $41 and $47 million.

For 2010, capital expenditures are expected to be approximately $12 to $15 million and depreciation is expected to be $22 to $24 million.

The financial information contained in this press release is unaudited, subject to revision and should not be considered final until the 2009 Form 10-K is filed with the SEC.

Basis of Reporting

The Company has provided a reconciliation from adjusted and other non-GAAP amounts to GAAP amounts at the end of this press release.  Management believes that this basis of reporting provides a more meaningful representation of the Company's historical operating results for the periods presented due to the magnitude and nature of certain recorded expenses in prior years.

Conference Call and Webcast

The Conference Call to discuss fourth quarter 2009 results will begin at 8:30 a.m. Eastern Time on Thursday, February 11, 2010 and last approximately 45 minutes.  Those wishing to participate should call 1-888-634-4003 for domestic and +1-706-634-6653 for international.  Please use the pass code 54652678 and call approximately 10 minutes prior to start time.  A webcast is available from the Investors section on the Cambrex website located at www.cambrex.com and can be accessed for 30 days follo
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... GenoSpace , a precision medicine software company that has developed ... of genomic, imaging and other biomedical data in research and ... , CEO of Aspera, an IBM Company, to its board ... "We are pleased to welcome Michelle ...
(Date:12/25/2014)... The report “Service Quality Management and Telco Customer Experience ... Global Advancements, Worldwide Forecasts & Analysis (2014-2019)” defines and ... of revenues. , Browse 152 market data tables, ... on “Service Quality Management (SQM) and Telco Customer Experience ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... patient care in critical areas, announced the closing of an ... warrants to purchase up to an aggregate 3,500,000 shares of ... and $.01 per warrant.  The warrants have a per share ...
(Date:12/24/2014)... BioLife Solutions , Inc. (NASDAQ: BLFS ), a ... hypothermic storage and cryopreservation freeze media and ... ("BioLife" or the "Company"), today announced that it will hold ... (the "Annual Meeting"). Because the expected date for ...
Breaking Biology Technology:GenoSpace Expands Board with Appointment of Michelle Munson 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2
... AEterna Zentaris Inc. (NASDAQ: AEZS ; TSX: ... on endocrine therapy and oncology, today announced that ... clinical development of the growth hormone secretagogue (GHS) ... be the first oral diagnostic test approved for ...
... BEIJING, Oct. 19 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. ... medical device,company that develops, manufactures and markets advanced in-vitro ... for its SPR-,based analysis system (the "SPR System") from ... , The SPR System utilizes ...
... , PHILADELPHIA, Oct. 17 UCB today announced data ... function, pain and fatigue of rheumatoid arthritis (RA) as ... of structural joint damage (seen at week 24) following ... was sustained up to 100 weeks. Cimzia® is approved ...
Cached Biology Technology:AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 2AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency 3China Medical Technologies Announces the SFDA Approval for its SPR System 2China Medical Technologies Announces the SFDA Approval for its SPR System 3UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 2UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 3UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 4UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 5UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 6UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 7UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 8UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 9UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 10UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 11UCB's Cimzia(R) (certolizumab pegol), Shows Rapid and Sustained Clinical Response in Adult Patients Living with Moderate to Severe Rheumatoid Arthritis 12
(Date:1/22/2015)... NXTD and NXTDW) a biometric authentication company focused on ... Wocket™ smart wallet at CES 2015 in Las Vegas ... the "11 Hot Products at CES" in a review published in Wired.com, ... Newseveryday.com and "The top 10 gadgets from CES 2015" by Danny ...
(Date:1/22/2015)... NEW YORK , Jan. 22, 2015   EyeLock, Inc. ... announced it has appointed Steve Gerber to the ... Gerber will be responsible for leading development of mobile platforms ... 25 years of success and innovation in the semiconductor industry ...
(Date:12/22/2014)... , Dec. 22, 2014  The 2014 Holiday Season may ... Acuity Market Intelligence reports that the long anticipated floodgates ... that intensifying demand for smart phones, tablets, and wearable ... market of 2.5 billion users with nearly 4.8 billion ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2
... A team composed of Harvard students and alumni was ... 2008 Development Marketplace competition, held in Accra, Ghana from ... cell-based lighting systems suitable for Sub-Saharan Africa, netted the ... Bank, as only 26 percent of Africas population has ...
... Its a paradox that has confounded evolutionary biologists since ... Since parasites depend on their hosts for survival, why do ... Emory University study of monarch butterflies and the microscopic parasites ... strike a middle ground between the benefits gained by reproducing ...
... a stalwart stand-in for humans in medical research, thanks ... genes may behave differently in mouse and man, a ... and Jianzhi Zhang reveals. Their results, which have ... human disease, appear in the current issue of the ...
Cached Biology News:Undergraduates develop 'dirt-powered' microbial fuel cells to light Africa 2Undergraduates develop 'dirt-powered' microbial fuel cells to light Africa 3Monarch butterflies help explain why parasites harm hosts 2Monarch butterflies help explain why parasites harm hosts 3Mouse can do without man's most treasured genes 2Mouse can do without man's most treasured genes 3
... ErbB 2 - BSA and Azide ... tested applications). Antigen: ... KLH, corresponding to C terminal amino ... Entrez GeneID: 2064 ...
SHP-2 Antibody...
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
Biology Products: